Introduction
============

Antimicrobial resistance (AMR) is a global concern, as it threatens the effective treatment of infectious diseases (<http://www.who.int/antimicrobial-resistance/en/>; last accessed November 27, 2017). *Pseudomonas aeruginosa* is a representative nosocomial pathogen showing AMR, and a major cause of death in patients with cystic fibrosis ([@evx243-B18]; [@evx243-B35]). In addition to having intrinsic drug resistance mechanisms, this bacterium is able to acquire exogenous genes, resulting in the emergence of multidrug-resistant (MDR) strains of *P. aeruginosa*, which are resistant to carbapenems, aminoglycosides, and fluoroquinolones. As MDR *P. aeruginosa* has a major impact on medical practice ([@evx243-B43]), knowledge of the mechanisms underlying multidrug-resistance to antibiotics and the epidemiology of MDR *P. aeruginosa* will be necessary to overcome infections with these bacteria.

*Pseudomonas aeruginosa* resistance to carbapenems and aminoglycosides was shown to be mediated by the acquisition of drug resistance genes ([@evx243-B15]; [@evx243-B26]), whereas resistance to fluoroquinolones is mediated by gene mutations ([@evx243-B5]). Acquisition of genes encoding several families of β-lactamases has been found to contribute to resistance to carbapenems, such as IMP and VIM ([@evx243-B34]). Similarly, acquisition of exogenous genes encoding several types of aminoglycoside-modifying enzymes, such as AAC ([@evx243-B32]) and 16S rRNA methylases ([@evx243-B44]), was shown to contribute to aminoglycoside resistance. In contrast, mutations in target genes, including those encoding DNA gyrase (*gyrA* or *gyrB*) and topoisomerase IV (*parC* and *parE*), were found to contribute to fluoroquinolone resistance ([@evx243-B5]). Interestingly, drug resistance genes acquired by MDR *P. aeruginosa* differ markedly among communities in various countries ([@evx243-B43]; [@evx243-B37]).

Epidemiological studies utilizing multilocus sequence typing (MLST; [http://pubmlst.org/perl/bigsdb/bigsdb.pl? page=pubmlst_paeruginosa_isolates](http://pubmlst.org/perl/bigsdb/bigsdb.pl?page=pubmlst_paeruginosa_isolates); last accessed November 27, 2017), a powerful molecular method for typing bacteria, can help understand and identify current MDR *P. aeruginosa* strains worldwide. These epidemiological studies showed that *P. aeruginosa* sequence type (ST) 235 is the predominant global clinical isolate ([@evx243-B43]; [@evx243-B12]; [@evx243-B36]; [@evx243-B24]; [@evx243-B10]; [@evx243-B6]; [@evx243-B42]; [@evx243-B22]), with 88.3% of MDR *P. aeruginosa* isolates resistant to carbapenems, aminoglycosides, and fluoroquinolones being classified as ST235 ([@evx243-B21]). Despite the importance of this subgroup, and despite the first ST235 *P. aeruginosa* being isolated in 1997, the mechanism underlying its persistence remains largely unknown.

To address the key traits responsible for its emergence and to identify the novel features of MDR *P. aeruginosa*, whole genome sequence (WGS) analysis was performed on *P. aeruginosa* strains isolated from hospital patients between 2001 and 2013 throughout Japan, as well as in other countries. In this study, MDR *P. aeruginosa* was defined according to the criteria of the Ministry of Health, Labour, and Welfare of Japan ([@evx243-B20]), because the definition of MDR *P. aeruginosa* varied among previous studies ([@evx243-B11]).

Materials and Methods
=====================

*Pseudomonas aeruginosa* Isolates
---------------------------------

MDR *P. aeruginosa* strains were collected based on the criteria specified by the Ministry of Health, Labour, and Welfare of Japan, including resistance to fluoroquinolones (minimum inhibitory concentration \[MIC\] ≥ 4 µg/ml), carbapenems (MIC ≥ 16 µg/ml), and amikacin (MIC ≥ 32 µg/ml; [@evx243-B20]). Several nonMDR *P. aeruginosa* strains were also included in this study ([supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Of the 185 clinical isolates evaluated by WGS analyses, 158 were from Japan, one from Thailand, three from Vietnam, seven from Nepal, and 15 from Poland. Also tested was the nonMDR *P. aeruginosa* strain PAO1 (USA). These isolates were grown on LB medium, and genomic DNA was purified using DNeasy Blood & Tissue kits (Qiagen). This study also included 26 *P. aeruginosa* strains registered in the database through 2012. Data including MLST and the genes or regions carried by each isolate are summarized in [supplementary data 1 and 4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online. In addition, 150 nonMDR *P. aeruginosa* isolates were screened to assess the frequency of ST235 *P. aeruginosa* among these nonMDR isolates.

WGS and Secondary Analyses
--------------------------

Nextera paired-end multiplex libraries of the isolates were generated and sequenced on a Genome Analyzer IIx (Illumina), according to the manufacturer's instructions, to generate 93-bp paired-end reads. More than 110-fold coverage was archived for each isolate. In some experiments, MiSeq (Illumina) was used to generate 251-bp paired end reads. The sequence data have been registered in the DNA Data Bank of Japan (DDBJ) under accession numbers DRA002419, DRA001216, and DRA001252. To identify SNPs among the isolates, all reads were assembled de novo into contigs using CLC Genomics Workbench (CLC bio), and the resulting contigs were concatenated by 60 × "*n*" gap filling and used as a reference genome. To identify SNPs among the 136 ST235 isolates, reads from each were aligned against the genome sequence of a reference ST235 strain, NCGM2.S1 ([@evx243-B29]), excluding regions of prophages and integrons ([supplementary table 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), to obtain high-quality concatenated SNP sequences. The average quality of the SNPs identified was Qv35, covered by \> 95% of the total reads.

MLST Analysis, O-type Analysis, and Analyses of Gene Distributions
------------------------------------------------------------------

MLST typing of all isolates was performed using the MLST plug-in of CLC Genomics Workbench with the MLST scheme for *P. aeruginosa* ([@evx243-B8]). The O-type of each O-type sequence was also determined using CLC Genomics Workbench. To analyze the distribution of drug resistance genes contributing to resistance against β-lactams, carbapenems, and aminoglycosides, as well as the distribution of genes contributing to *oprD* disruption and to the acquisition of exogenous genetic materials, Illumina reads of each isolate were assembled de novo and the resulting contigs were searched with the BLAST algorithm ([@evx243-B2]) for each gene or region using CLC Genomics Workbench. The numbers of CIRSPRs and spacers were analyzed using CRISPRfinder (<http://crispr.i2bc.paris-saclay.fr>; last accessed November 27, 2017; [@evx243-B13]). Genes for CRISPR-associated proteins (CASs) harbored by *P. aeruginosa* retrieved from the NCBI database ([supplementary table 2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) were used as queries to search for genes encoding CAS in *P. aeruginosa* strains used in this study. These results are presented in [supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online.

Phylogenetic Analyses
---------------------

Concatenated SNP sequences were aligned with MAFFT ([@evx243-B19]). Evolutionary models (TVM + I + G for analysis of the 185 isolates and TVM + G for analysis of the 136 ST235 isolates) were chosen based on the results obtained with jModelTest 2.1.2 ([@evx243-B33]) and convergence of the trees during preliminary phylogenetic analyses. Maximum-likelihood phylogenetic trees were constructed for the total 185 isolates and for the 136 ST235 isolates by concatenated SNPs with PhyML 3.0 ([@evx243-B14]). The probability for node branching was evaluated with 100 bootstraps. In BEAST phylogeny of the 136 ST235 isolates, a clock model was chosen based on preliminary analyses showing better convergence of the tree. All other parameters were set to default, with chain lengths of 895,564,000 states and resampling every 10,000 states. Effective sample sizes (ESS) were \>200 for all parameters. Time from the appearance of the most recent common ancestor was estimated using BEAST ([@evx243-B9]) and Path-O-Gen v1.4 (<http://tree.bio.ed.ac.uk/software/pathogen/>; last accessed November 27, 2017) programs.

Results
=======

WGS analysis was performed on 156 MDR and 29 sensitive or nonMDR *P. aeruginosa* isolates (total 185 isolates) collected from patients throughout Japan and in other countries, including Thailand, Vietnam, Poland, and Nepal ([supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). To determine the genetic relationships among these isolates, phylogenetic analysis was performed based on SNP concatenation. As the *P. aeruginosa* genome shows a high degree of plasticity, it is not sufficient to map Illumina reads to a particular *P. aeruginosa* genome. Thus, to determine sequence information on all of these isolates, the reads from all 185 libraries were assembled de novo, yielding 8,930 contigs (17,592,198 bp). These contigs were concatenated and used as the reference sequence to map reads from each isolate and to determine high-quality SNPs. A total of 249,067 SNPs were identified, and these concatenated SNP sequences were used to reconstruct a maximum-likelihood phylogenetic tree by MEGA5 ([@evx243-B41]; [fig. 1](#evx243-F1){ref-type="fig"}). One hundred thirty six of the 185 isolates (73.5%) were clustered into a ST235 clade, with 125 of these 136 isolates (80.1%) found to be MDR *P. aeruginosa*, consistent with findings of previous studies ([@evx243-B6]; [@evx243-B21]; [@evx243-B20]; [@evx243-B47]), indicating that ST235 was the predominant clade in these *P. aeruginosa* isolates. Strikingly, screening of 150 nonMDR *P. aeruginosa* clinical isolates identified only two ST235 isolates, indicating that ST235 isolates are significantly enriched in the MDR *P. aeruginosa* population (chi-square test, *P* \< 0.001).

![---Phylogenic tree of the 185 *Pseudomonas aeruginosa* strains. The unrooted phylogeny of all *P. aeruginosa* strains was based on the maximum-likelihood method using PhyML 3.0 ([@evx243-B14]). Each sequence type with more than one isolate \[i.e. ST27 (*n* = 2), ST111 (*n* = 3), ST235 (*n* = 136), ST244 (*n* = 3), ST274 (*n* = 2), ST277 (*n* = 5), ST357 (*n* = 11), ST966 (*n* = 4), ST1284 (*n* = 2), and ST1342 (*n* = 4)\] is indicated in color. Scale bar: 0.04 substitutions per variable site. Each main branch had \>99% bootstrap support.](evx243f1){#evx243-F1}

Divergence within Subclades of ST235
------------------------------------

As ST235 was the dominant MDR *P. aeruginosa* isolates, we analyzed the detailed relationships of the 136 ST235 isolates based on a Bayesian phylogenetic tree ([@evx243-B9]) and a maximum-likelihood phylogenetic tree constructed using the concatenated SNP sequence of these 136 ST235 isolates ([fig. 2](#evx243-F2){ref-type="fig"} and [supplementary fig. 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). The SNPs of each ST235 strain were compared with a representative ST235 MDR *P. aeruginosa* strain, NCGM2.S1 ([@evx243-B29]). To determine the genetic backbone of these isolates, SNPs located in mobile elements, such as prophages and integrons ([supplementary table 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online), were omitted from the concatenations. Phylogenetic analysis therefore included 34,926 SNPs. Bayesian phylogeny was thought to be more robust than maximum likelihood phylogeny, based on posterior probability (values for all subclades were \> 0.99) and bootstrap values, respectively. Therefore, each subclade was analyzed in detail based on Bayesian phylogeny.

![---Phylogenic tree of the 136 ST235 *Pseudomonas aeruginosa* strains. The phylogeny of ST235 MDR *P. aeruginosa* strains was evaluated using the BEAST program ([@evx243-B9]). The seven subclades are shown in color. The estimated ages of the branches are shown as median values with 95% highest posterior density (HPD). The proportion of isolates from each location carrying conserved antibiotic resistance genes (\>50% per subclade) and their *oprD* disruption status are also indicated. The posterior probability value for each main branch was \>0.99. More detailed results are shown in [supplementary figure 2](#sup1){ref-type="supplementary-material"} and [supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online. The posterior probability of each subclade designated was \> 0.95.](evx243f2){#evx243-F2}

The Bayesian phylogenetic tree resulted in the clustering of the 136 ST235 isolates into seven subclades ([fig. 2](#evx243-F2){ref-type="fig"}). NP9, which was isolated from a patient in Nepal, was not included in any clade and was far separated from the other clades. Interestingly, NP9 was the only isolate expressing New Delhi metallo-beta-lactamase-1 (NDM1). The isolate from Thailand was clustered in subclade 5 and the isolates from Poland in subclades 4 and 7. None of the isolates from Vietnam was classified as ST235.

Assessments of the relationships between phylogenetic results and the geographic location of the isolates in Japan ([fig. 2](#evx243-F2){ref-type="fig"}, and [supplementary fig. 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) showed that all isolates in subclade 3 were from one prefecture in Eastern Japan and most of the isolates in subclade 4 were from Western Japan. Six of the 11 isolates in subclade 7 were from Poland, with most of the remaining subclades being from Eastern Japan. The geographical distribution of isolates in each subclade suggests that the ancestors of each clade had spread on a global scale. Comparison of unique SNPs in each subclade with the genome of NCGM2.S1 ([supplementary table 3](#sup1){ref-type="supplementary-material"} and [supplementary data 2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) showed that subclades 3 and 4 had specific regions with unique SNPs; for example, 1,956,904_1,968,105 (NCGM2_1807 to NCGM2_1819) and 4,195,981_4,221,917 (NCGM2_3853 to NCGM2_3884) in subclades 3 and 5,270,138_5,299,359 (NCGM2_4888 to NCGM_4926) and 5,796,989_5,802,393 (NCGM2_5407 to NCGM2_5412) in subclade 4. The geographic location and the accumulated unique SNPs in regions in each subclade, especially in subclades 3 and 4, suggest that each subclade evolved independently following its emergence in different communities after separation from their ancestors. Because some isolates obtained from countries other than Japan were closely related with subclades that included isolates from Japan such as subclades 4 and 5, the ancestors of these isolates were likely present in different countries independently.

More than 50% of the drug-resistance genes were conserved in multiple subclades ([fig. 2](#evx243-F2){ref-type="fig"}, [supplementary fig. 1](#sup1){ref-type="supplementary-material"} and [supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). The genes *blaTEM, imp1 or 6*, *aac(6′)-Iae* and *aadA1* were conserved in subclades 1, 2, and 3; *aac(3)-Ic*, *aac(6′)-Ib*, *aacA4* and *aadA2* were conserved in subclades 5 and 6; and *imp7* was conserved in subclade 6. In addition, *oxa-2*, *aacA7*, *aacA8*, and *aadA6* were conserved in subclade 4, and *aac(6′)-lb-cr*, *aacA4*, *aadA6*, and *aphA15* were conserved in subclade 7. These gene distribution patterns indicate that each subclade harbors specific drug resistance genes.

Subclades could also be distinguished by disruption of the *oprD* gene, which has been reported associated with carbapenem resistance ([@evx243-B25]; [@evx243-B40]). In the prototype ST235 MDR strain, NCGM2.S1, which was clustered in subclade 1, *oprD* was found to be disrupted by insertion of an integron harboring *imp-1* and *aac(6′)-Iae*([@evx243-B29]). Disruption of *oprD* was highly prevalent in isolates of subclades 1 and 2, with 52 of 62 (83.9%) harboring *imp-1* and 55 of 62 (88.7%) harboring *aac(6′)-Iae*. The isolates in subclades 1 and 2 may have derived from a common ancestor containing an integron harboring *imp-1* and *aac(6′)-Iae* and spread throughout Eastern Japan.

Bayesian phylogenetic analysis also suggested that the most recent common ancestor of ST235 appeared ∼74.1 (95% highest posterior density, 71.2--76.9) years ago and that branching within each subclade occurred ∼20--40 years ago ([fig. 2](#evx243-F2){ref-type="fig"}). Additionally, Path-O-Gen (<http://tree.bio.ed.ac.uk/software/pathogen/>; last accessed November 27, 2017), a tool for investigating the temporal signal and "clocklikeness" of molecular phylogenies, suggested that the most recent common ancestor of the 136 ST235 isolates emerged ∼86.0 years ago. These results suggest that after emergence, the ancestors of these subclades were separated, with each acquiring particular drug resistance genes over the last 20--40 years, possibly coincident with the increased availability of antibiotics, such as aminoglycosides and carbapenems. The acquisition of drug resistance genes may have led to the expansion of each subclade over the past several decades.

Taken together, phylogenetic evidence suggests that several outbreaks accompanied the clonal expansion of ST235 MDR *P. aeruginosa* over the past several decades, and that these outbreaks may have been the driving force behind the generation of the population structure of ST235 MDR *P. aeruginosa* in Japan.

High Substitution Rate in ST235 MDR *P. aeruginosa*
---------------------------------------------------

Bayesian analyses suggested that the estimated substitution rate of ST235 MDR *P. aeruginosa* was between 6.44 and 8.66 × 10^−4^ (95% highest posterior density) substitutions per site per year ([fig. 3](#evx243-F3){ref-type="fig"}). This substitution rate is at least 100-fold higher than those of other bacterial species ([@evx243-B16]; [@evx243-B7]; [@evx243-B31]; [@evx243-B17]). We analyzed the genome sequences of *P. aeruginosa* isolates, determined at least at the scaffold level registered in the database (<https://www.ncbi.nlm.nih.gov> hereafter referred to as "genome strains," [supplementary table 4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online) with the same parameters. The results showed a substitution rate of 4.3 ×10^−6^ to 1.0 × 10^−5^, which was lower than that of ST235 MDR *P. aeruginosa* ([fig. 3](#evx243-F3){ref-type="fig"}). These results suggested that the substitution rate of genomes in the ST235 *P. aeruginosa* isolates was relatively high.

![---Substitution rate of various bacteria, including ST235 *Pseudomonas aeruginosa*. Comparison of reported substitution rates of MRSA ([@evx243-B16]), *Streptococcus pneumonia* ([@evx243-B7]), *Salmonella typhimurium* ([@evx243-B31]), *Clostridium difficile* ([@evx243-B17]), ST235 MDR *P. aeruginosa*, and *P. aeruginosa* ([supplementary 4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). The substitution rates of *P. aeruginosa* were estimated using the BEAST program ([@evx243-B9]).](evx243f3){#evx243-F3}

Unique Features of ST235 MDR *P. aeruginosa*
--------------------------------------------

To examine why ST235 isolates are dominant among MDR *P. aeruginosa*, we analyzed genes not having homologs in the representative nonMDR *P. aeruginosa* strains PAO1 and LESB58, but found uniquely in ST235 *P. aeruginosa.* Of the 827 genes found to be conserved in NCGM2.S1, but not in PAO1 or LESB58, 466 were present at frequencies \>95% in the 136 ST235 *P. aeruginosa* strains ([supplementary table 5](#sup1){ref-type="supplementary-material"} and [supplementary data](#sup1){ref-type="supplementary-material"} 3, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). We identified five regions in ST235 isolates (NCGM2_1785 to NCGM2_1844, NCGM2_1949 to NCGM2_1963, NCGM2_3701 to NCGM2_3710, NCGM2_3761 to NCGM_3772, and NCGM2_5888 to NCGM2_5904) containing unique genes with high density. Although four of these regions contained genes that presumably contribute to metabolism or are annotated as hypothetical proteins, one region, NCGM2_1785 to NCGM2_1844, showed a high degree of similarity to a region previously identified as an ExoU island in *P. aeruginosa* 6077 ([@evx243-B23]). This region encodes type IV secretion systems (T4SS), which have been extensively characterized and shown to mediate conjugation, uptake, and release of DNA, as well as effector translocation ([@evx243-B1]; [@evx243-B3]; [@evx243-B45]; [@evx243-B38]; [@evx243-B39]). The T4SS harbored by \>95% of 136 ST235 strains analyzed in this study was the Tfc type ([supplementary fig. 2](#sup1){ref-type="supplementary-material"} and table 6, [Supplementary Material](#sup1){ref-type="supplementary-material"} online, NCGM2.S1 was used as the representative), which contributes to conjugation ([@evx243-B30]). PAO1 harbors nine genes or clusters, including competence-associated genes and T4SS, highly identical to genes in other *P. aeruginosa* strains ([supplementary fig. 3](#sup1){ref-type="supplementary-material"} and [supplementary data 4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). In contrast to PAO1, the additional T4SS found in ST235 isolates was not conserved among the *P. aeruginosa* strains, except for the ST235 strain 39016. Strains negative for the additional T4SS, such as PAO1 and LBSE58, did not harbor any drug resistance genes, suggesting that ST235 strains with additional T4SS are prone to acquisition of exogenous genetic material.

Absence of CRISPR/CAS System in ST235 *P. aeruginosa*
-----------------------------------------------------

Additional genetic traits affecting the acquisition of exogenous genetic material have been reported to cluster in regularly-interspaced short palindromic repeats (CRISPRs) and in CASs (CRISPR/CAS; [@evx243-B4]; [@evx243-B46]). CRISPRs rely on small RNAs for sequence-specific detection and silencing of foreign nucleic acids, including bacteriophages and plasmids. Although the distributions of CRISPRs and CASs differed among the 26 *P. aeruginosa* genome strains, the ST235 isolates NCGM2.S1 and 39016 did not harbor more than one confirmed CRISPR and had relatively few CRISPR spacers ([supplementary fig. 3](#sup1){ref-type="supplementary-material"} and [supplementary data 4](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online). Furthermore, NCGM2.S1 and 39016 may not harbor recognizable CAS1 proteins. To confirm this tendency, the numbers of CRISPRs and spacers among the 136 ST235 *P. aeruginosa* strains were counted, using CRISPRfinder (<http://crispr.i2bc.paris-saclay.frlast>; accessed November 27, 2017; [@evx243-B13]). Remarkably, most ST235 isolates did not harbor confirmed CRISPRs and spacers, with the numbers of both varying in other ST isolates. We also analyzed whether the 136 ST235 strains harbored the 149 genes encoding CASs of *P. aeruginosa* listed in [supplementary table 2](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online. The results indicated that none of the ST235 isolates harbored genes encoding CAS except for only 2 strains (PA1604, PL3220) (for PA1604: *csf1*, *csf2*, *csf3*, and *csf4*; for PL3220: *cas1 cas6/csy4*, and *csf2*; [supplementary data 1](#sup1){ref-type="supplementary-material"}, [Supplementary Material](#sup1){ref-type="supplementary-material"} online).

These results suggest that ST235 strains without the CRISPR/CAS system are prone to acquisition of exogenous genetic material.

Discussion
==========

In this study, the features of MDR *P. aeruginosa* were determined by WGS analyses of 185 *P. aeruginosa* isolates isolated from hospitalized patients. MLST analysis showed that ST235 was the predominant clonal ST lineage, being identified in 136 of the 185 strains. These 136 strains, consisting of isolates from Japan and other countries, could be divided into seven subclades, each of which had specific features, including conserved drug-resistance genes, geographic location and genomic background. Estimates suggested that the most recent common ancestor of these ST235 isolates arouse ∼80 years ago, with each subclade radiating over a few decades. These findings suggest that the ancestor of each subclade emerged over a few decades and spread in particular communities. WGS analysis also showed that ST235 MDR *P. aeruginosa* had a higher substitution rate, an additional T4SS, and no functional CRIPSR/Cas interference. These genetic traits may enable these bacteria to acquire exogenous genetic elements more efficiently, as well as increasing the intrinsic high competency of *P. aeruginosa*. Most currently used antibiotics were developed and used in patients from the 1960s to the 1980s. The acquisition of resistance to commonly used antibiotics, whether by substitution or the acquisition of drug resistance genes, may be the driving force behind the persistence and expansion of MDR ST235 *P. aeruginosa* in hospitals over the last several decades. Selection pressure from antibiotic treatment would allow the expansion of particular strains, such as ST235, that efficiently acquire substitution and drug resistance genes.

In conclusion, these results provide clues to the mechanism underlying the emergence and spread of MDR *P. aeruginosa* in particular communities and the key traits of the predominant ST235 MDR *P. aeruginosa* strain.
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